Volpara CEO confident of strong finish to 2019

Volpara Health Technologies Ltd (ASX: VHT) is a junior SaaS business based in New Zealand.

| More on:
Healthy Heart

This morning medical software player Volpara Health Technologies Ltd (ASX: VHT) reported an operating cash loss of NZ$4.24 million on sales of NZ$4.89 million for the quarter ending September 30, 2019. The company flagged a ‘one off’ payroll timing adjustment for a blow out in staff costs that dragged the overall quarterly result lower.

It also completed the acquisition of Seattle-based breast screening business MRS Systems in the prior quarter to distort comparisons to prior corresponding quarters.

Volpara reported annualised recurring revenue (ARR) including the MRS acquisition was NZ$15.7 million (US$10.3m) as at September 30 2019. The group is now selling software to assist in the detection of both breast and lung cancer.

After a A$55 million capital raising in June 2019 the company has NZ$40.9 million cash on hand and is forecasting a cash outflow of NZ$8.97 million in the December quarter.

The CEO, Ralph Highnam, is confident of a big December quarter: “We’re very much looking forward to Q3 with the delivery of new integrated products at RSNA (Radiological Society of North America), our big trade show in Chicago; the publication of the DENSE results from the Netherlands after a 10-year randomised control trial using Volpara®DensityTM software; and a possible breast density announcement from the FDA (US Food and Drug Administration).”

Based on 218 million shares on issue Volpara is valued around $357 million based on a $1.64 share price.

We can see why it was keen to get a capital raising away at a $1.50 per share back in June and the company’s share price is perhaps flying higher than its financial results.

Others in the medtech space flying high include Pro Medicus Limited (ASX: PME) and Nanosonics Ltd (ASX: NAN).

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

Tom Richardson owns shares of Pro Medicus Ltd and Dicker Data.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Nanosonics Limited and VOLPARA FPO NZ. The Motley Fool Australia has recommended Nanosonics Limited, Pro Medicus Ltd., and VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News